Market Access News | pharmaphorum

News

What next for pharma as SCOTUS strikes down Trump tariffs?

The centrepiece of President Trump's economic strategy has been shattered after the Supreme Court ruled his sweeping tariffs are illegal.

News

FDA starts review of Regeneron's drug for rare disease FOP

Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?

News

Woman on crutches, left-hand side of her body, face not revealed

UK firm steps in to ease medicine supply crisis in NHS

Amid reports that a shortage of bone cement in the UK is leading to delayed orthopaedic surgeries, Biocomposites has brought forward a product launch.

News

Texas sues Sanofi, claiming kickbacks to doctors

Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, claiming the company bribed doctors to prescribe its medicines.

News

Scrabble lettering of Two and One on grass

Makary says FDA will "end two-trial dogma" for approvals

The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new medicines on two pivotal trials.

News

The word Diabetes surrounded by tablets and syringes

NICE backs changes to NHS' diabetes care pathway

New guidance from NICE on type 2 diabetes management will shake up NHS treatment, with wider use of both SGLT2 inhibitors and GLP-1 agonists.

What next for pharma as SCOTUS strikes down Trump tariffs?

FDA starts review of Regeneron's drug for rare disease FOP

UK firm steps in to ease medicine supply crisis in NHS

Texas sues Sanofi, claiming kickbacks to doctors

Makary says FDA will "end two-trial dogma" for approvals

NICE backs changes to NHS' diabetes care pathway

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks